Video

REVIEW UroToday

SNMMI Case of the Month VL

Search

The Intricacies and Potential of PSMA PET/CT in Modern Salvage Radiation Planning - Philipose Mulugeta Details Philipose Mulugeta presents the SNMMI Case of the Month, focusing on the use of PSMA PET/CT for salvage radiation planning in the context of biochemical recurrence. The case involves a 73-year-old patient with a history of radical prostatectomy in 2017, salvage radiation therapy in 2021, and a rising PSA trend. Despite previous negative imaging results, the patient underwent a PSMA PET/CT, reveali...
Lutetium-177 Therapy Yields Outstanding Response in Chemo-Naive Prostate Cancer Patient - Nasrin Ghesani Details Nasrin Ghesani shares a case of a 71-year-old prostate cancer patient's significant recovery with lutetium-177 therapy. Initially diagnosed in 2012, the patient underwent numerous treatments including a radical prostatectomy and hormone therapies, before transitioning to lutetium PSMA-617 therapy in 2022. Despite temporary treatment delays, the patient saw undetectable PSA levels and no tumor remn...
Localized Prostate Carcinoma: Discordant Findings on mpMRI and PSMA PET Case of the Month - Devaki Shilpa Surasi Details Devaki Shilpa Surasi presents a case of localized prostate carcinoma with conflicting results on multiparametric MRI and PSMA PET. The patient had a biopsy confirming prostate adenocarcinoma, and the MRI showed a diffuse lesion with extraprostatic spread and seminal vesicle involvement. However, the PSMA PET indicated minimal PSMA activity in the prostate, suggesting a PSMA-negative lesion. Treatm...
The Utility of PSMA PET for a Patient with Metastatic Castrate-Resistant Prostate Cancer Case of the Month - Ephraim Parent Details Ephraim Parent presents a case highlighting the utility of PSMA PET for a patient with metastatic castrate-resistant prostate cancer. The PSMA PET scan revealed discordant disease, with soft tissue predominantly FDG-avid and the osseous disease either matching hypermetabolic and PSMA-avid lesions or predominantly PSMA. Based on these findings, the patient was determined to be inappropriate for Plu...
Heterogeneity of PSMA Uptake in Prostate Cancer - SNMMI Case of the Month - Akintunde Orunmuyi Details In this Society of Nuclear Medicine and Molecular Imaging (SNMMI) case of the month lecture, Akintunde Orunmuyi presents a case-based presentation evaluating the heterogeneity of PSMA uptake in prostate cancer. The patient presented with advanced prostate cancer who has not received any treatment. Notably, his serum PSA was low in comparison to the extent of disease on PSMA PET/CT scan. The PSMA s...
Using Gallium PSMA PET to Evaluate Progression and Eligibility for Lutetium-177 PSMA Therapy - Bennett Chin Details In this Society of Nuclear Medicine and Molecular Imaging (SNMMI) case of the month lecture, Bennett Chin presents a patient case of a 73-year-old man with advanced prostate cancer at diagnosis who was referred for a gallium PSMA PET CT to evaluate for progression as well as to evaluate eligibility for lutetium-177 PSMA. Despite persistent disease, this patient has a low PSA on presentation. Dr. C...